FDA ex­plains why it re­ject­ed Van­da's stom­ach drug in late 2024

Rarely does the FDA pub­licly re­lease its rea­son­ing for re­ject­ing a po­ten­tial new drug. But for DC-based Van­da Phar­ma­ceu­ti­cals’ gas­tro­pare­sis drug, the FDA on Wednes­day …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER